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Edited by Hans-Dieter KlenkAbstract Hepatitis B virus (HBV) is a DNA virus which repli-
cates via reverse transcription. The structure and function of the
reverse transcriptase play important roles in HBV replication.
We have previously reported that when proline at residue 306
in HBV reverse transcriptase was substituted by other amino
acids, most of the mutants showed decreased replicative compe-
tency. To explore the mechanisms for this decrease in replicative
competency, constructs with substituted amino acid residues at
rtP306 were used to transfect Huh-7 cells, and replication com-
petencies, transcription levels and encapsidation eﬃciencies of
the mutants and the parental viral strain were compared.
Decreased replication competency was found with many of the
mutants and conﬁrmed by trans-complementation between each
mutant and a replication-defective replicon. No change in tran-
scriptional level was detected between all mutated constructs.
The encapsidation competencies of these constructs were studied
by assaying pregenomic RNAs in intracytoplamic core particles
from transfected cells, which were normalized for the amount of
HBV core protein by Western blotting using anti-core antibod-
ies. Impaired encapsidation was found in several mutants substi-
tuted at residue 306, thereby demonstrating for the ﬁrst time that
conservation of proline at this residue is crucial for eﬃcient
encapsidation of pregenomic RNA.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatitis B virus (HBV) is a major cause of chronic viral
hepatitis [1] and may lead to liver cirrhosis and hepatocellular
carcinoma [2,3]. HBV belongs to the Hepadnaviridae, and pos-Abbreviations:HBV, hepatitis B virus; pgRNA, pregenomic RNA; RT,
reverse transcriptase; EPR, endogenous polymerase reaction
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doi:10.1016/j.febslet.2007.01.024sesses a circular genome approximately 3.2 kb in size which
replicates through an RNA intermediate (pregenomic RNA,
pgRNA) [4]. The viral genome consists of four open reading
frames, namely, the envelope gene (Pre-S/S), the core gene
(Pre-C/C), the X gene (encoding the transactivating X protein)
and the polymerase gene (P) [4]. The P gene covers approxi-
mately three-fourth of the coding region and overlaps with
each of the three other genes [4]. By mutational analysis and
by sequence alignment with the corresponding retroviral
reverse transcriptase (RT), the HBV polymerase can be divided
into four domains: the terminal protein (TP), which is unique
to HBV and used as a protein primer to initiate reverse
transcription; the spacer region, dispensable for polymerase
activity; the RT domain, bearing a YMDD (tyrosine-methio-
nine-aspartic acid-aspartic acid) motif to catalyze RNA and
DNA dependent DNA polymerization, and the RNaseH
domain, which degrades the RNA strand of RNA–DNA
hybrids produced during HBV reverse transcription [5].
HBV polymerase plays multiple roles in HBV replication
cycle. TP domain acts as a protein primer to initiate reverse
transcription using the stem–loop structure (e) close to the 5 0
end of pgRNA as the template [6–10]. Progeny viral DNA syn-
thesis is then accomplished by sequential action of the RNA
dependent DNA polymerase, RNaseH and DNA dependent
DNA polymerase activities of the HBV polymerase [4]. In
addition, HBV polymerase participates as a necessary compo-
nent in the assembly of capsids together with pgRNA, core
proteins and cellular factors such as Hsp90 and p23 [7,11–
17]. To date, eight genotypes of HBV have been reported
[18,19], and a poorer prognosis is associated with certain geno-
types [20].
We previously reported that substitutions of proline at resi-
due 306 of RT domain of polymerase (rtP306) of a genotype B
HBV with alternative amino acids led to altered virus replica-
tion [21,22]. To explore the possible mechanisms involved in
this eﬀect on replicative competency, we constructed mutants
with diﬀerent amino acids substituted at rtP306 of a genotype
C HBV strain. By monitoring the replication competencies,
pgRNA encapsidation eﬃciencies and endogenous polymerase
activity, critical roles of rtP306 in replication competency and
virus encapsidation are shown.blished by Elsevier B.V. All rights reserved.
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2.1. Plasmid constructs
An HBV replicon plasmid harboring 1.3 copies of HBV genome was
constructed following standard methods. In brief, 3.2 kb of a full-
length HBV genome fragment cleaved from plasmids pUC-HBV#97
(Genotype C, GenBank accession number: AF411411) by SapI (New
England Biolab) was self-ligated with T4 DNA ligase (New England
Biolab). Using the ligated products as templates, two fragments (A
and B) were respectively ampliﬁed with the following primers: A: 5 0-
AAACTGCAGCTGCCTGTAAATAGACCTATTG-3 0/5 0-GCTGT-
AGCTCTTGTTCCCAAG-3 0; B: 5 0-CTCAGTCCGTTTCTCCT-
GGC-3 0/5 0-CGGGGTACCGAGAGTAACTCCACAGAAG CTC-3 0
(Sequences underlined denote recognition sites of PstI and KpnI,
respectively). Fragment A was digested by PstI and BstEII (New
England Biolab), while fragment B was cut with SpeI and KpnI
(New England Biolab). HBV replicon plasmid was completed through
a two-step cloning strategy: digested fragment A was ﬁrstly cloned into
pUC-HBV#97 between PstI and BstEII restriction sites, subsequently
digested fragment B was inserted into the SpeI–KpnI sites of the recom-
binant plasmid pUC-HBV#97-A. This recombinant plasmid was
replication competent.
The following mutations (rtP306G, P306A, P306S, P306V, P306D,
P306L, P306E, P306K and P306F) were then introduced into this plas-
mid by overlapping PCR as described previously [22]. A non-replica-
tive mutant rtW58*, which has a stop codon at residue 58 in the RT
domain, was constructed as described by Roychoudhury et al. [17].
This mutant was used for trans-complementation study.
To construct a eukaryotic expression plasmid for HBV core protein,
550-bp from the core coding sequence was ampliﬁed from pUC-
HBV#97 with the primers: 5 0-GTCTAGCTAGCGCCACCATGGA-
CATTGACACCTATAAAG-3 0/5 0-CGGGGTACCCTAACATTGA-
GATTCCCGAGAT-30 (sequences underlined denote recognition sites
of NheI and KpnI, respectively). This was cloned into the NheI and
KpnI sites of pcDNA3.1/Hygro() (Invitrogen) to obtain pcDNA-
core. Huh-7 cells transfected with this plasmid DNA can express the
core proteins, which self-assembles into core particles [23].
For the trans-complementation assay, 2.5 kb of coding sequences of
the wild type HBV#97 polymerase and its mutants (rtP306A, P306S,
P306V, P306G, P306E) were tagged at their 5 0 termini with 3·FLAG
sequence (Sigma) to facilitate their detection by Western blotting (per-
sonal communication, Wang Shick Ryu, Yonsei University). These
were separately ampliﬁed by PCR and cloned into the NheI and Hin-
dIII sites of pcDNA3.1/Hygro().
To generate the template for the HBV speciﬁc antisense riboprobe, a
460-bp HBV sequence (1376–1840, the X gene) from HBV replicon
plasmid was ampliﬁed by the following primers: 5 0-CGGGGTACCT-
TAGGCAGAGGTGAAAAAGTTG-3 0/5 0-GCTCTAGAATGGCT-
GCTAGGATGTGCTG-3 0 (sequences underlined represent recogni-
tion sites of KpnI and XbaI, respectively) and cloned into pBluescript
SK (+) (Stratagene) to construct pBlue-X. For in vitro transcription,
pBlue-X was ﬁrst linearized with XbaI (New England Biolab), precip-
itated and dissolved in DEPC water.2.2. Cell culture and transfection
Huh-7 cells (hepatocarcinoma cell line) were cultured in DMEM
(Invitrogen) supplemented with 10% fetal bovine serum, 100 U/ml pen-
icillin G and 100 lg/ml streptomycin, 0.2 mM L-glutamine, in 5% CO2.
Ten micrograms of recombinant wild type or mutant HBV DNA and
5 lg pEGFP-C2 encoding a green ﬂuorescent protein (Clontech) or
pSEAP2-Control expressing secreted alkaline phosphatase (SEAP)
were co-transfected to Huh-7 cells by the calcium phosphate co-precip-
itation method [22]. SEAP activity in the culture media was detected as
reported previously [22]. Transfection experiments were repeated at
least twice and transfection eﬃciency in endogenous polymerase reac-
tion (EPR) was normalized by SEAP activity.2.3. Isolation of intracellular replicative intermediates from transfected
cells
As reported by Lin et al. [22], cells were lysed with lysis solution
(10 mM Tris–HCl, pH 7.9, 1 mM EDTA, 100 mM NaCl and 1%
NP-40) and incubated with DNase I, RNaseA and magnesium acetate
to remove free nucleic acids. After centrifugation at 12000 · g for
5 min, intracellular viral capsids in the supernatant were precipitatedwith 6.5% PEG8000 and 0.3 M NaCl, and digested with proteinase
K overnight. HBV DNA was extracted twice with phenol:chloroform
(1:1), precipitated with ethanol and 0.3 M sodium acetate, and dis-
solved in distilled deionized water.2.4. Southern blotting
As described by Lin et al. [22], HBV DNA isolated from capsids was
fractionated on 1% TAE agarose gels and transferred onto nylon mem-
branes. These were hybridized either at 60 C with a HBV single-strand
antisense riboprobe (produced by in vitro transcription using linear-
ized pBlue-X as the template with a riboprobe labeling kit (Promega)),
or at 42 C with HBV speciﬁc double-stranded 32P-labeled probes
prepared by random primer labeling (Roche diagnostics). The mem-
branes were washed and exposed to phosphorimage plates and scanned
by a phosphorimage reader (Fujiﬁlm). Densitometry of each lane was
performed using MultiGauge V2.2 software (Fujiﬁlm). Replication
eﬃciencies of each mutant were indicated by the amount of intracellu-
lar viral replicative intermediates of each mutant normalized for the
amount of capsids protein detected by Western blotting.2.5. Northern blotting
Total cellular RNA was extracted from transfected cells with Trizol
reagent (Invitrogen). Following the standard method [24], 20 lg of
RNA was separated on agarose/formaldehyde gels, transferred onto
nylon membranes and ﬁxed by UV irradiation. Hybridization and
exposure were similar to that described for Southern blotting. To nor-
malize for transfection eﬃciency and amount loaded, EGFP mRNA
was determined using an EGFP speciﬁc probe prepared as mentioned
above.2.6. Trans-complementation assay
Five lg pEGFP-C2 and 10 lg polymerase-depleted replicon rtW58*
DNA were mixed with either 10 lg 3·FLAG tagged wild type poly-
merase or its mutant vectors. These were used to transfect Huh-7 cells
as above. Following standard methods, the levels of input 3·FLAG
tagged polymerase or EGFP were detected by Western blotting using
mouse-derived monoclonal anti-FLAG antibody (M2, Sigma) or rab-
bit-derived polyclonal anti-EGFP antibody (New England Biolab),
followed by HRP-labeled anti-mouse or anti-rabbit secondary anti-
bodies (Amersham Pharmacia Biotech). Intracellular replicative inter-
mediates were extracted and monitored by Southern blotting.2.7. HBV pgRNA packaging assay
HBV pgRNA packaging eﬃciency was determined as reported [25–
27]. In brief, transfected cells were lysed as described above, centri-
fuged at 12000 · g for 2 min, and 40 ll supernatant was electrophore-
sed on a native agarose gel and transferred onto a nitrocellulose
membrane. The amount of assembled capsid protein was measured
by Western blot using polyclonal anti-HBcAg (Dako), HRP-labeled
anti-rabbit secondary antibody (Amersham Pharmacia Biotech) and
chemiluminescence reagents (Pierce). Subsequently, the same mem-
brane was treated with 0.2 M NaOH/1.5 M NaCl for 30 s followed
by neutralization with 0.2 M Tris–HCl, pH 7.4/1.5 M NaCl for
5 min to release nucleic acids in the capsids. Encapsidated pgRNAs
were then detected using a 32P-labeled antisense riboprobe as men-
tioned above. The packaging eﬃciency was calculated by the signal
intensity of encapsidated pgRNA normalized to that of the corre-
sponding capsid protein.2.8. Endogenous polymerase reaction
As described by Radziwill et al. [5], transfected cells were lysed and
intracellular core particles were immunoprecipitated with protein A
sepharose CL-4B beads coated with polyclonal anti-HBcAg. After
washing, reaction buﬀer containing 50 mM Tris–HCl, pH 7.5,
75 mM NH4Cl, 1 mM EDTA, 20 mM MgCl2, 0.1% (vol/vol) b-
mercaptoethanol, 0.5% (vol/vol) Nonidet P-40, 0.4 mM dATP,
0.4 mM dGTP, 0.4 mM dTTP and 10 lCi [a-32P] dCTP (3000 Ci/
mmol) was added to the beads. Following incubation, labeled capsid
DNA was released with proteinase K treatment, recovered and sepa-
rated on a 1% TAE agarose gel, and transferred onto a Nylon mem-
brane. The membrane was exposed to a phosphorimage plate and
scanned by a phosphorimage reader (Fujiﬁlm).
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3.1. Replicative phenotype of a genotype C HBV (#97) replicon
The genotype C HBV (#97, Genbank No. AF411411) repli-
con (Fig. 1A) bearing 1.3· the full-length HBV genome, repli-Fig. 1. Immature replicative phenotype of HBV (#97) replicon. (A)
Schematic diagram of a 1.3· full-length HBV genome and sites
targeted by the antisense riboprobe. (B) Southern blotting of intracel-
lular replicative intermediates of HBV replicon (#97). Lane 1 was
detected with antisense riboprobe; lane 2 was monitored by HBV
speciﬁc double-stranded probes after stripping the riboprobe. 4.2 kb
DNA fragments, i.e. 1.3· the full-length HBV genome released from
the replicon plasmid, were used as a positive control.
Fig. 2. Replication and encapsidation eﬃciencies of mutants substituted at
replicative intermediates produced from rtP306 mutants. (B) Hybridization
capsids and detected with the antisense riboprobe. (C) Western blotting analy
rtP306 mutants. (D) Calculated replication and encapsidation eﬃciencies of m
are deﬁned in Section 2. Samples used for these experiments were derived from
below each panel, and the value of wild type strain is arbitrarily set to 1.
detectable.cated eﬃciently in Huh-7 cells, when detected by the HBV
speciﬁc double-stranded probes. Nevertheless this replicon
showed reduced synthesis of 4.0 kb relaxed circular (RC)
DNA (Figs. 1B and 2A). Besides, when detected by the plus-
strand speciﬁc riboprobe (Fig. 1A), plus-strand viral DNA
could not be detected (Fig. 1B). DNA sequence analysis of
core gene revealed a leucine residue at codon 97 (data not
shown). This intracellular phenotype of WT-#97 strain is con-
sistent with the previous report by Chiaho Shih’s group [28].3.2. Replication competencies of mutants with substitutions at
residue rtP306 of a genotype C replicon
Genotype C HBV strain (#97) plasmids with rtP306 substi-
tuted by nine diﬀerent amino acids with increasing lengths of
the side chains (namely rtP306G, P306A, P306S, P306V,
P306D, P306L, P306E, P306K and P306F) were transfected
into Huh-7 cells and their replicative competencies were com-
pared (Fig. 2). Replication competencies (Fig. 2D) were de-
ﬁned as the amount of intracellular viral replicative
intermediates (Fig. 2A) normalized for the amount of capsid
protein detected by Western blotting (Fig. 2C). When the rep-
lication eﬃciency of WT-#97 was set as 1.00, the relative rep-
licative eﬃciencies of all nine mutants were less than 1.00
(Fig. 2A, C and D). When rtP306 was substituted by glycine,
the replication eﬃciency was reduced more than 8-fold, and
when substituted by aspartic acid, leucine, glutamic acid, lysinertP306. (A) Southern blotting of intracellular capsid-associated viral
analysis of encapsidated pgRNA released in situ from intracellular
sis using polyclonal anti-HBcAg of intracellular capsids produced from
utants substituted at rtP306. Replication and encapsidation eﬃciency
the same cell transfection experiment. Scanned grey values are shown
00. RE, replication eﬃciency; EE, encapsidation eﬃciency; ND, non
Fig. 3. (A) Schematic diagram showing that the location of rtP306 overlaps the 5 0 modulator element of HBV enhancer I. Enhancer I (966–1308
nucleotide sequence) denoted as an open rectangle consists of three parts: the 5 0 modulator element, the core element contributing to HBV replication
level and the 3 0 end overlapping with the X promoter. The binding motifs of liver-speciﬁc transcription factors, hepatocyte nuclear factor 3 (HNF3)
and hepatocyte nuclear factor 4 (HNF4) are indicated as black boxes. A part of the HBV polymerase ORF, RT and RNaseH, are represented as a
grid rectangle. The location of rtP306 is shown as a black star. Enh I, enhancer I. (B) Northern blotting analysis of transcripts of HBV mutants
substituted at rtP306. EGFP mRNA in each lane was used for normalization of transfection eﬃciency and as a loading control.
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were also drastically reduced. However, when rtP306 was re-
placed by alanine, serine or valine, replication eﬃciencies were
only slightly decreased (91%, 41% and 39%, respectively)
(Fig. 2D).
3.3. Northern blot analysis of the transcription of the mutants
Because the coding sequence of rtP306 overlaps with the 5 0
modulatory domain of enhancer I (Fig. 3A), whose core ele-
ment was shown to play an important role in the transcription
of HBV pgRNA [29,30], we studied whether amino acid substi-
tutions at rtP306 would aﬀect transcription of HBV pgRNA.
Total cellular RNA was extracted from Huh-7 cells transfected
with the mutants substituted at rtP306, and assayed by North-
ern blotting and hybridization with HBV speciﬁc probe.
Results showed that none of the substitutions at rtP306 inter-Fig. 4. Trans-complementation assay of rtW58* by the substituted RT
mutants. Huh-7 cells were co-transfected with the polymerase depleted
replicon rtW58* and eukaryotic expression vectors of 3·FLAG tagged
WT-#97 polymerase or its mutants substituted at rtP306. The upper
box shows Southern blotting analysis of intracellular viral replicative
intermediates; the middle box shows Western blotting analysis of
3·FLAG tagged WT-#97 polymerase or its mutants; the lower box
shows expression levels of EGFP used for normalization of transfec-
tion eﬃciency and as a loading control. *, degraded product of EGFP.fered with transcription levels when normalized with that of
EGFP mRNA (Fig. 3B).
3.4. Trans-complementation of an incompetent replicon by
rtP306 mutants
To verify whether substitutions at rtP306 indeed impaired
virus replication, rtW58* (Fig. 2A) was co-transfected into
Huh-7 cells together with diﬀerent 3·FLAG tagged polymer-
ase mutants containing substitutions at rtP306. The 3·FLAG
tagged wild type #97 polymerase could eﬃciently trans rescue
the replication of rtW58*, while 3·FLAG tagged polymerase
mutants with substitutions at rtP306 (rtP306A, P306S,
P306V, P306G and P306E) either partially rescued or failed
to rescue rtW58* (Fig. 4). As shown by Western blotting, the
expression levels of 3·FLAG tagged polymerase from wild
type #97 and from diﬀerent RT mutants were similar
(Fig. 4), which indicated that substitutions at rtP306 did not
alter the stability of HBV polymerase.
3.5. Analysis of the encapsidation eﬃciencies of mutants with
substitutions at rtP306
Using the speciﬁc pgRNA encapsidation assay developed by
Yu and Summers [27], the pgRNA encapsidation eﬃciencies of
the rtP306 mutants were studied. In this assay, capsids from
cytoplasmic lysates were separated by native agarose gel elec-
trophoresis and detected by Western blotting. Subsequently,
plus-strand nucleic acids composed of encapsidated pgRNA
and progeny plus-strand viral DNA were released in situ from
the capsids by alkaline lysis. Since plus-strand viral DNA
could not be detected by the antisense riboprobe (Fig. 1B),
the encapsidated pgRNA would be the only product detected
by the same antisense riboprobe. The pgRNA encapsidation
eﬃciency of each mutant was deﬁned as the amount of
in situ released pgRNA (Fig. 2B) normalized to that of viral
capsid protein (Fig. 2D). To verify the speciﬁcity of the encaps-
idation assay, three controls were included. The ﬁrst control
included the antiviral drug 3TC in the replication and encaps-
idation study in cell transfection assay. Since 3TC only inhibits
Fig. 5. Endogenous polymerase reaction of mutants substituted at
rtP306. Amounts of isotope incorporation shown at the bottom of the
panels were calculated when the scanning signal intensity of wild type
strain was set as 1.00. ND, non detectable.
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pgRNA encapsidation. As shown in Fig. 2, 3TC did inhibit
the replication of #97 but had no eﬀect on the encapsidation
of pgRNA. The second control used polymerase-depleted rep-
licon rtW58; as this mutant could not replicate in transfected
cells, and no pgRNA packaging would be expected. The third
control was transfection with pcDNA-Core plasmid. This plas-
mid would produce large amount of core particles but these
would not package HBV speciﬁc RNA. Results of the controls
in this study were consistent with previous encapsidation
assays described by others [15,17,31].
Using this assay and denoting the encapsidation eﬃciency of
wild type strain #97 as 1.00, when rtP306 was substituted by
glutamic acid, aspartic acid, leucine, lysine or phenylalanine
the packaged pgRNA was below the detection limit (shown
in Fig. 2B–D). When rtP306 was replaced by glycine, the
encapsidation eﬃciency was decreased to 29% of that of wild
type strain (#97). However, pgRNA encapsidation eﬃciencies
were not impaired or only slightly impaired when rtP306 was
substituted by alanine, serine or valine (Fig. 2D).
3.6. Analysis of the polymerase activity of mutants
To date, two major roles have been assigned to HBV poly-
merase, which are: taking part in viral encapsidation and
nucleotidyl transfer to produce progeny viral DNA. Unfortu-
nately, due to the low expression level, instability and insolu-
bility of the HBV polymerase, biochemical assays in vitro
are not available to fully conﬁrm its nucleotidyl transfer activ-
ity [26,32]. Since the encapsidation eﬃciencies of rtP306A,
P306S and P306V (120%, 79% and 88%, respectively) were
not impaired or only slightly impaired, while their replication
eﬃciencies were, respectively decreased to 91%, 41% and
39% of that of wild type strain, we used a classical assay, the
EPR [5], to monitor the nucleotidyl transfer activity of poly-
merase in HBV capsids from wild type virus and its mutants
(rtP306A, P306S and P306V). Under identical assay conditions
the amounts of isotope incorporation representing viral DNA
synthesis by rtP306A, P306S and P306V were only 58%, 49%
and 30% of the wild type strain respectively (Fig. 5). Therefore,
substitutions of rtP306 with alanine, serine or valine seemed to
aﬀect the nucleotidyl transfer activity of polymerase. As
expected, for other mutants (rtP306G, P306E) which showed
severely impaired pgRNA encapsidation (Fig. 2B), no viral
DNA synthesis could be observed by EPR (Fig. 5).4. Discussion
HBV replication is a complex process, in which, the initia-
tion of reverse transcription utilizes the terminal protein do-
main at the amino terminal of the polymerase as a protein
primer [9,10,33] and a speciﬁc packaging signal (e) located at
the 5 0-end of viral pgRNA as the template [6–8,11,34–36]. This
is followed by assembly of nucleocapsids and subsequent syn-
thesis of progeny virus DNA. In addition, the participation of
cellular chaperone proteins are also needed to complete the
replication cycle of HBV [14,15,26]. Functional HBV polymer-
ase is crucial in this replication cycle. However, due to the lack
of in vitro infection system, the replication competencies of
various HBV strains or their mutants can only be studied by
cell transfection assays [22]. Furthermore, because enzymati-cally active HBV polymerase cannot be produced in suﬃcient
amount in vitro for crystallographic analysis [26,32], the three
dimensional structure of HBV RT has not yet been solved.
Amino acid substitutions at residue rtP306 in a genotype B
HBV strain was previously reported to interfere with virus rep-
lication [21,22]. In this study, this phenomenon was further
veriﬁed in a genotype C HBV strain (#97) and the mechanisms
involved were explored. Substitutions of rtP306 with nine dif-
ferent amino acids led to diﬀerent degrees of decreased replica-
tion eﬃciencies. Furthermore, the decreased replication
pattern was shown to be amino acid type dependent: a trend
for greater inhibitory eﬀects was seen when the side chains of
the substituted amino acids (rtP306D, P306L, P306E, P306K
and P306F) had more carbon atoms than those (rtP306A,
P306S and P306V) with less carbon atoms in their side chains
(Fig. 2D). Interestingly, the replicative phenotypes of some
mutants (especially rtP306D, P306E) were not in accordance
with the previous ﬁndings in a genotype B HBV strain, where
they had shown increased replication eﬃciencies [21]. This
could be attributed to diﬀerent viral genotypes or to diﬀerent
cells used for transfection.
In this study, the decreased replication competencies of the
mutants with substitutions at rtP306 were further veriﬁed
through the trans-complementation assay (Fig. 4), and these
results conﬁrmed that conservation of rtP306 was indeed
important for eﬀective replication competency. Northern blots
ruled out the possibility that substitutions at rtP306 interfered
with HBV transcription (Fig. 3), and Western blot analysis
demonstrated that substitutions at rtP306 did not alter the sta-
bility of HBV polymerase protein (Fig. 4). It is known that
aside from progeny DNA synthesis, HBV polymerase plays
an important role in virus encapsidation [7,11–17]. By using
the encapsidation assay, we have shown that impaired encaps-
idation eﬃciency was one major mechanism for the decreased
replication competencies of several mutants with amino acid
substitutions at rtP306. Similarly to the decreased replication
eﬃciencies, the pattern of decreased pgRNA encapsidation
eﬃciency was also amino acid type dependent (Fig. 2D).
Y.-X. Wang et al. / FEBS Letters 581 (2007) 558–564 563From this study, it is evident that a conserved rtP306 is cru-
cial for optimal encapsidation of pgRNA, and substitutions at
this residue with amino acids can hamper the encapsidation
process. A plausible interpretation for the amino acid type-
dependent eﬀect on encapsidation is that certain amino acid
substitutions at rtP306 (e.g. rtP306G, P306D, P306L, P306E,
P306K, P306F) may change the conformation of HBV poly-
merase to impair its functions in virus encapsidation. HBV
encapsidation is a dynamic and complex process. In this pro-
cess, active interactions between polymerase and core proteins,
polymerase and pgRNA, and polymerase and cellular factors
have been suggested [15,26,37]. How these interactions were
impaired when residue rtP306 was changed needs further clar-
iﬁcation in the future. In mutants (e.g. rtP306A, P306S and
P306V) that only slightly aﬀected pgRNA encapsidation eﬃ-
ciency, their EPR showed an approximately twofold decrease
in nucleotidyl transfer activity. In these particular mutations,
this eﬀect might be the mechanism for the decreased replicative
competency.
Taken together, we have used mutational analysis to extend
our previous ﬁnding that a conserved rtP306 was crucial for
high replication competency. In this study, we have shown that
the major mechanism for decreased replication eﬃciency in
many rtP306 mutants was the impaired pgRNA encapsidation,
while in some other mutants, decreased nucleotidyl transfer
activity of the polymerase was also observed. The involvement
of rtP306 in HBV polymerase function suggests that targeting
this residue could lead to new measures to block the encapsida-
tion and replication of HBV.Acknowledgements: We are grateful to Professor Yung-Chi Cheng
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